Clinical trial protocol design is one of the most important stages in drug development. Decisions made during protocol development can influence patient selection, study duration, statistical power, operational complexity, regulatory acceptance, and ultimately the quality of evidence generated by the trial.
Among these decisions, endpoint selection deserves particular attention. A well-chosen endpoint should reflect a meaningful clinical question, align with the study objective, and be supported by appropriate scientific and regulatory evidence. Yet clinical development teams often have to make these decisions while navigating large volumes of historical protocols, published studies, trial registries, clinical guidelines, and competitor programmes.
This is where benchmarking can add value.
Modern clinical trial protocol design software, powered by pharma clinical trial intelligence, can help teams compare protocol characteristics against relevant historical and contemporary evidence. Instead of treating endpoint selection as an isolated scientific decision, teams can examine how similar studies have defined primary and secondary endpoints, what populations were used, how outcomes were measured, and how trial designs evolved over time.
With the right evidence infrastructure, benchmarking can become a structured part of protocol development rather than a final validation exercise.
What Is Clinical Trial Protocol Benchmarking?
Clinical trial protocol benchmarking is the process of comparing a proposed trial design with relevant evidence from previous and ongoing studies.
The comparison may include:
The objective is not to copy an earlier protocol.
Every clinical trial has its own scientific question, development stage, patient population, and operational constraints. Benchmarking instead provides context for understanding whether a proposed design is consistent with established approaches or represents a deliberate departure from them.
A protocol team might discover, for example, that similar Phase III studies commonly use a particular clinical outcome as the primary endpoint, while newer studies increasingly incorporate patient-reported outcomes or biomarker-based secondary measures.
That information can help researchers ask better questions before finalising the protocol.
Why Endpoint Selection Matters
Endpoints determine what a clinical trial is designed to measure.
The primary endpoint is particularly important because it generally represents the main outcome used to address the study's primary objective. Secondary and exploratory endpoints can provide additional evidence about efficacy, safety, quality of life, biological activity, or other outcomes of interest.
Poorly considered endpoint choices can create challenges throughout the development process.
An endpoint may be difficult to measure consistently, insufficiently sensitive to treatment effects, poorly aligned with the clinical question, operationally burdensome, or difficult to interpret.
Conversely, a well-supported endpoint can make the trial more scientifically coherent and help teams establish a clearer relationship between the research question, study design, analysis, and evidence generated.
This is why endpoint selection should be based on more than precedent. Historical usage can provide useful context, but scientific rationale and the intended clinical question must remain central.
How Evidence Can Support Endpoint Selection
Evidence-based endpoint selection begins by identifying the most relevant sources.
Depending on the therapeutic area and development stage, these may include:
Previous clinical trials
Clinical trial registries
Peer-reviewed publications
Regulatory guidance
Treatment guidelines
Systematic reviews
Meta-analyses
Standard-of-care evidence
Competitor trial protocols
Patient-reported outcome research
Natural-history studies
The challenge is that these sources are often distributed across different databases and document types.
Researchers may need to manually compare dozens or hundreds of trials to understand which endpoints have been used, how frequently they appear, and how their definitions differ.
AI-enabled evidence workflows can reduce this burden by extracting structured information from multiple sources and presenting it in a format that supports comparison.
A protocol benchmarking tool can help clinical development teams turn historical trial information into structured benchmarks.
For example, a team developing a new study might define a benchmarking set based on:
Same therapeutic area
Same indication
Similar disease severity
Similar mechanism of action
Same development phase
Comparable patient population
Similar treatment duration
Relevant comparator
The system can then compare the proposed protocol against the selected evidence set.
This could reveal patterns such as the prevalence of particular endpoints, typical assessment time points, commonly used patient populations, or changes in endpoint strategy across development phases.
The quality of the benchmark depends heavily on how the comparison set is defined. Comparing a proposed Phase III oncology trial with every oncology trial ever conducted would produce little useful insight.
Benchmarking should therefore be contextual.
The Role of AI in Endpoint Selection
AI can make endpoint benchmarking more scalable by processing large volumes of scientific and clinical information.
An endpoint selection AI workflow could help identify endpoint patterns across relevant studies and organise information around questions such as:
Which endpoints are most commonly used in similar trials?
How have endpoint definitions changed?
Which endpoints appear most frequently as primary versus secondary outcomes?
What assessment time points are commonly selected?
Which patient-reported outcomes are being used?
How are competitors designing comparable studies?
Are newer trials adopting different endpoint strategies?
What evidence supports a particular endpoint?
The output should not be interpreted as an automatic recommendation.
AI can identify patterns, but clinical researchers must determine whether those patterns are scientifically appropriate for the proposed study.
This distinction is particularly important because frequency does not equal validity.
An endpoint may appear frequently because it is traditional or operationally convenient rather than because it is the best measure for a specific research question.
Benchmarking Primary Endpoints
Primary endpoints deserve the highest level of scrutiny because they are directly connected to the principal objective of the study.
Benchmarking can help researchers examine how comparable trials have addressed similar questions.
For example, researchers can assess:
Endpoint Type
Is the endpoint based on survival, disease progression, symptom improvement, functional outcomes, a clinical event, a biomarker, or another measure?
Endpoint Definition
How precisely is the outcome defined?
Two trials may appear to use the same endpoint while applying different definitions, assessment criteria, or thresholds.
Timing
When is the endpoint assessed?
Timing can influence both the scientific interpretation and operational requirements of the trial.
Measurement Method
How is the outcome measured, and who performs the assessment?
Historical Adoption
Has the endpoint been widely used in comparable studies, or is it relatively new?
Evidence Base
What clinical or regulatory evidence supports its use?
These questions provide much more value than simply counting how often an endpoint appears in previous trials.
Benchmarking Secondary and Exploratory Endpoints
Secondary endpoints can help address important questions beyond the primary objective.
They may provide additional evidence about:
Safety
Symptoms
Quality of life
Functional outcomes
Pharmacodynamic effects
Disease progression
Treatment response
Patient experience
Benchmarking can help identify which secondary outcomes are commonly included in comparable protocols and whether the proposed endpoint set provides a balanced view of the intervention.
Exploratory endpoints may be even more diverse.
These endpoints can support hypothesis generation or provide additional biological or clinical information, but they should still have a clear rationale.
AI can help organise these endpoint categories and identify emerging patterns without requiring researchers to manually inspect every protocol.
Using Competitor Trials for Benchmarking
Competitor trial intelligence can be especially valuable when designing studies in crowded therapeutic areas.
A development team may want to understand:
Which endpoints competitors are prioritising
Whether endpoint strategies are changing
How study populations differ
What comparators are being selected
Whether trial durations are increasing or decreasing
Which patient-reported outcomes are appearing more frequently
Whether emerging biomarkers are being incorporated
A dedicated pharma clinical trial intelligence capability can help teams monitor these developments and connect trial-level information with broader competitive evidence.
This type of intelligence is valuable because a protocol is developed within a changing clinical landscape.
A design that was competitive two years ago may look very different from the emerging standard today.
From Static Benchmarking to Continuous Intelligence
Traditional benchmarking is often performed at a particular point during protocol development.
The problem is that the clinical evidence landscape continues to change.
New competitor trials can begin. Existing studies can report results. Guidelines can change. New endpoints can gain acceptance. Regulators can publish new guidance.
AI-enabled monitoring can support a more continuous model.
Instead of asking only, "How does our protocol compare with historical studies?", teams can also ask:
"Has the benchmark changed since we started designing the protocol?"
This creates an opportunity for protocol development to become more dynamic.
Teams can establish an initial evidence benchmark and periodically reassess it as new clinical information becomes available.
Building Evidence Into Protocol Design
Benchmarking is most valuable when it is integrated directly into the protocol workflow.
A practical process could look like this:
Step 1: Define the Clinical Question
Clearly identify what the trial is designed to establish.
Step 2: Establish the Evidence Set
Identify comparable trials, publications, guidelines, and regulatory sources.
Step 3: Structure Protocol Variables
Extract endpoints, populations, comparators, time points, and other relevant design characteristics.
Step 4: Identify Patterns
Use analytics or AI to identify similarities, differences, and emerging trends.
Step 5: Evaluate Scientific Relevance
Clinical experts assess whether observed patterns are appropriate for the proposed trial.
Step 6: Document the Rationale
Record why particular endpoints and design decisions were selected.
Step 7: Continue Monitoring
Update the benchmark as important new evidence becomes available.
This creates a documented chain between evidence and protocol decisions.
We should think of adding visually appealing creatives like below in our blogs to make them attractive
Why Traceability Matters
AI can accelerate evidence analysis, but speed alone is not sufficient for clinical development.
Researchers need to know where an insight originated.
If an AI system identifies a recurring endpoint pattern, users should be able to trace that finding back to the underlying trials or publications.
A trustworthy workflow should therefore distinguish between:
Source evidence
Extracted information
AI-generated synthesis
Human interpretation
Final protocol decision
This separation improves transparency and makes it easier for teams to challenge or validate AI-assisted insights.
It also reduces the risk of treating an AI-generated recommendation as established scientific fact.
Pienomial and AI-Powered Clinical Trial Intelligence
Pienomial can support life sciences organisations that need to bring fragmented evidence together for faster, more informed decision-making.
Its clinical trial intelligence capabilities can help teams organise and analyse information around clinical studies, enabling researchers and strategic teams to monitor trial activity and identify relevant developments across the clinical landscape.
For protocol teams, this type of intelligence can provide useful context when evaluating trial design choices, understanding competitor approaches, and monitoring changes in endpoint strategies.
The value is not simply having more information.
It is being able to connect relevant information and turn it into structured intelligence that researchers can evaluate within the context of their specific development programme.
How Clinical Trial Protocol Design Software Can Improve the Workflow
The right clinical trial protocol design software can bring protocol planning and evidence intelligence closer together.
Instead of developing a protocol in isolation and conducting benchmarking separately, teams can use technology to connect the two activities.
A platform can help teams:
Retrieve comparable protocols and studies
Structure endpoint information
Compare study characteristics
Identify emerging design patterns
Track competitor trials
Organise supporting evidence
Maintain source references
Document protocol rationale
Monitor changes in the external landscape
This can reduce repetitive research while giving clinical development teams a more systematic basis for discussion.
However, software should support—not replace—the scientific and clinical judgment required to design a trial.
Common Mistakes in Protocol Benchmarking
Benchmarking can become misleading when teams apply it without sufficient context.
Using Too Broad a Comparison Set
A large number of irrelevant trials can obscure useful patterns.
Treating Frequency as Evidence of Quality
The most common endpoint is not automatically the most appropriate endpoint.
Ignoring Study Phase
Endpoint strategies can differ substantially between early- and late-stage development.
Overlooking Endpoint Definitions
Similar endpoint names can represent materially different measurements.
Relying Only on Historical Data
Older trials may not reflect current clinical practice or emerging evidence.
Treating AI Outputs as Decisions
AI can identify patterns, but qualified experts should determine whether those patterns support the proposed protocol.
Failing to Document the Rationale
A protocol decision should have a clear scientific basis that can be understood later.
A Better Model for Evidence-Backed Endpoint Selection
The future of protocol benchmarking is likely to combine structured evidence, AI-assisted analysis, clinical expertise, and continuous monitoring.
The workflow can be thought of as four connected layers.
Evidence: Collect relevant trial, publication, guideline, and regulatory information.
Intelligence: Use AI and analytics to identify patterns and relationships.
Expertise: Allow clinical and scientific professionals to evaluate whether those patterns are relevant.
Governance: Maintain traceability between sources, analysis, interpretation, and final decisions.
This model helps avoid two extremes.
The first is entirely manual benchmarking, which can be slow and difficult to scale.
The second is fully automated protocol design, which can create unacceptable risks when AI-generated recommendations are treated as authoritative.
The most useful model sits between these extremes.
Conclusion
Clinical trial protocol benchmarking can provide an important evidence layer for protocol development, particularly when teams need to make difficult endpoint decisions in rapidly changing therapeutic landscapes.
A modern clinical trial protocol design software environment can help researchers compare relevant studies, identify endpoint patterns, monitor competitor programmes, and connect protocol decisions to supporting evidence.
AI can make this process significantly more efficient. Endpoint selection AI can process large volumes of clinical information and surface patterns that would be difficult to identify manually. A protocol benchmarking tool can then turn those patterns into structured comparisons that support expert discussion.
But technology should remain an enabler.
The strongest protocol decisions come from combining high-quality evidence with clinical expertise, transparent reasoning, and appropriate governance.
For pharmaceutical organisations, the goal should not be to select endpoints because an algorithm says they are common. It should be to understand the evidence behind different endpoint strategies and make a defensible decision based on the clinical question, patient population, development stage, and broader scientific context.
Pienomial can help life sciences teams build this evidence-connected approach by bringing clinical trial intelligence and AI-assisted analysis into a more structured environment. As clinical development becomes increasingly data-intensive, protocol benchmarking can evolve from a one-time research exercise into a continuous intelligence capability that supports better-informed trial design.
